EHA Library - The official digital education library of European Hematology Association (EHA)
Magrolimab + Aza for AML - Slideset Download - Clinical Oncology 2022 | CCO
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
Forty Seven (FTSV) On A Roll, Up Over 300% In 2 Months
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
Magrolimab combination with azacitidine enhances therapeutic... | Download Scientific Diagram
Magrolimab - Multiple Myeloma Clinical Trials
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
Brian Skorney on Twitter: "Magrolimab + aza data out. CR rate in 2019 was 50% in high risk MDS. Down to 42% in 2020. Now 33% today. Contrast with 32% CR with
CD47-SIRPα Drug Target Minireview - Drug Hunter
PhI/II AZA/VEN/MAG - Slideset Download - | CCO
ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert
Guidance for transfusion management in patients receiving magrolimab therapy (anti‐CD47 monoclonal antibody) - Tan - 2022 - Internal Medicine Journal - Wiley Online Library
Effect of CD47 Blockade on Vascular Inflammation | NEJM
ASCO News - Magrolimab in Combination with Azacitidine Demonstrates Durable Activity in Untreated MDS & AML | Leukemia and Lymphoma Society
EHA Library - The official digital education library of European Hematology Association (EHA)
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients | Leukemia and Lymphoma Society
Magrolimab for Solid Tumors Clinical Trial 2023 | Power
New directions for emerging therapies in acute myeloid leukemia: the next chapter | Blood Cancer Journal
Frontiers | Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
